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Abstract
Nanoscale metal-organic frameworks (NMOFs) of the UiO-66 structure containing high Zr (37 wt
%) and Hf (57 wt%) content were synthesized and characterized, and their potential as contrast
agents for X-ray computed tomography (CT) imaging was evaluated. Hf-NMOFs of different sizes
were coated with silica and poly(ethylene glycol) (PEG) to enhance biocompatibility, and were
used for in vivo CT imaging of mice, showing increased attenuation in the liver and spleen.
Introduction
X-ray computed tomography (CT) is a widely used biomedical imaging technique that is
capable of providing three-dimensional images with excellent spatial resolution.1, 2 It is an
important tool for diagnosing and monitoring diseases and abnormalities throughout the
body.3 CT is based on differences in X-ray attenuation, and a contrast agent is often used to
enhance the contrast between the tissue of interest and its surroundings.3–6 Materials with
high electron density have high X-ray attenuation, therefore elements with high atomic
numbers (high-Z elements), like iodine, gold, bismuth, and gadolinium, have been
considered for use as contrast agents. However, the only CT contrast agents currently
approved for clinical use are iodinated aromatic molecules for vascular and organ imaging
and barium sulfate for gastrointestinal tract imaging. The utility of CT imaging with small-
molecule contrast agents is limited by their nonspecific distribution, rapid renal clearance,
and fast extravasation from blood and lymphatic vessels.3–6 As a consequence, large doses
of small molecule contrast agents (typically 30 g of I or 70 g total material) must be
administered to achieve adequate contrast, sometimes causing adverse reactions for the
patients.3, 5
Many of the limitations of molecular contrast agents can be overcome by nanoparticulate
contrast agents that can carry a high payload and be functionalized to increase blood
circulation times and to endow target specificity.7 Nanoparticles do not readily diffuse into
extravascular space or undergo rapid renal clearance, thus allowing adequate time for
accumulation at a disease site. Several nanoparticle systems including Bi2S3,8 gold,9, 10 and
iodinated organic nanoparticles,11–13 have recently been evaluated as next-generation CT
contrast agents. However, it is still challenging to formulate nanoparticles with high
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loadings of high-Z elements that are also nontoxic and able to be cleared from the body in a
timely fashion. We previously reported nanoparticles of one-dimensional iodinated
coordination polymers as potential CT contrast agents.14 While these iodinated coordination
polymer nanoparticles had several advantages over molecular contrast agents and other
types of nanoparticles, they did not possess adequate stability to be further functionalized
and used in vivo. Metal-organic frameworks (MOFs) are crystalline three-dimensional
coordination polymers composed of organic bridging ligands that are coordinatively bonded
to metal ions or metal ion clusters.15–18 The synthesis and development of a new class of
nanomaterials has recently been demonstrated by scaling down MOFs to the
nanoregime.19, 20 These nanoscale MOFs (NMOFs) have already shown great potential in
biosensing,21 magnetic resonance imaging,22, 23 and drug delivery.24
In this work, NMOFs containing high-Z elements are synthesized and their potential as CT
contrast agents is evaluated. Instead of incorporating the high-Z element into the bridging
ligand of the structure as in our earlier work,14 the high-Z elements (hafnium and zirconium)
are incorporated into NMOFs in the M6(μ3-O4)(μ3-OH)4(RCO2)12 (M = Zr or Hf)
secondary building units. While clinically-used contrast agents are iodinated molecules,
iodine is not the best choice for a contrast agent in terms of X-ray attenuation efficiency, but
is used mainly due its low toxicity and low cost.6 Elements with higher attenuation at
relevant X-ray photon energies could provide adequate contrast at a lower dose and decrease
the amount of radiation to which a patient must be exposed.
UiO-66 is a MOF composed of the Zr-carboxylate cluster Zr6(μ3-O4)(μ3-OH)4(RCO2)12,
which serves as a secondary building unit, bridged by benzenedicarboxylate linkers.25
UiO-66 is more chemically, thermally, and mechanically stable compared to other MOFs,
owing mainly to the strength of the Zr-carboxylate bond.26 While Zr has an atomic number
of 40, which may make it useful as a component of a CT contrast agent, Hf shows similar
chemical behaviors and has an even higher atomic number (72). Therefore, a Hf analog of
the Zr UiO-66 MOF has been made for the first time, and has been evaluated as a CT
contrast agent in vivo.
Experimental
Materials and methods
All starting materials were purchased from Fisher or Aldrich and used without further
purification. Proton nuclear magnetic resonance spectroscopy (1H NMR) spectra were
recorded on a Bruker NMR 400 at 400 MHz and referenced to the proton resonance
resulting from incomplete deuteration of deuterated dimethyl sulfoxide (DMSO-d6, δ 2.50).
Thermogravimetric analysis (TGA) was performed using a Shimadzu TGA-50 equipped
with a platinum pan, and all samples were air-dried and heated at a rate of 4 °C per minute
under air. Scanning electron microscopy (SEM) was used to image the particles, using a
Hitachi 4700 field emission scanning electron microscope. A Cressington 108 Auto Sputter
Coater equipped with a Au/Pd (80/20) target and an MTM-10 thickness monitor was used to
coat the samples with a conductive layer before taking SEM images. Each SEM sample was
prepared by first suspending the nanomaterial in ethanol, then a drop of the suspension was
placed on a glass slide and the solvent was allowed to evaporate. Transmission electron
microscopy (TEM) was obtained on a JEOL 100CX-II Transmission Electron Microscope
using carbon-coated copper grids to hold samples. Size and zeta potential information was
obtained on a Malvern ZetaSizer dynamic light scattering instrument. Infrared spectroscopy
(IR) was performed using a Bruker Alpha-T Fourier Transform Infrared Spectrometer in
attenuated total reflectance (ATR) mode. Powder X-ray diffraction (PXRD) analyses were
carried out using a Bruker SMART Apex II diffractometer using Cu radiation. The PXRD
patterns were processed with the Apex II package using the phase ID plugin.
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CT phantom and in vivo images and X-ray attenuation data were obtained using a micro-
computed tomography scanner equipped with a carbon nanotube based field emission micro-
focus X-ray source. All CT scans were done at 50 kVp, 0.7 mA, 0.5 mm Al filtration, and 50
msec exposure per projection. Four hundred projections were used over a circular orbit of
200° at a step angle of 0.5° and were reconstructed at 76 μm isotropic voxel spacing. In vivo
imaging was carried out using protocol approved by University of North Carolina
Institutional Animal Care and Use Committee. The animals were anesthetized with 1–2%
isoflurane at a flow rate of 1.5–2 L min−1 from a vaporizer. The anesthetized animals were
placed over the pressure sensor in the mouse sample holder and secured with adhesive
restraints. The animals were put in the prone position such that the respiration sensor was
approximately in the position of the abdomen to achieve maximum sensor coupling. To
obtain the cardiac signals, ECG electrodes were taped to the footpads. With the camera
running at 1 frame per second, the scan time was typically 15–20 min depending on the
mouse respiration and heart rates.
Synthesis of PEG and nanoscale metal-organic frameworks
Synthesis of triethoxysilylpropyl carbamoyl-poly(ethylene glycol)2000 ((OEt)3Si-PEG2000-
OCH3): 1.00 g (0.50 mmol) of poly(ethylene glycol)-2000 monomethylether was dried
under vacuum at 100 °C for 5 h. After cooling the PEG to room temperature, it was
dissolved in 4 mL anhydrous dimethyl sulfoxide (DMSO). 0.124 mL (0.50 mmol) of
distilled (3-isocyanatopropyl)triethoxysilane was then added, followed by 1 μL (0.742 mg,
5.7 μmol) of diisopropylethylamine (Hünig’s base). The reaction was stirred at room
temperature under N2 for 12 h. The DMSO was removed under vacuum at 60 °C. 1H NMR
(DMSO-d6, 400 MHz): 0.51 (t, 2H), 1.14 (t, 9H), 1.43 (t, 2H), 2.92 (q, 2H), 3.35 (s, 3H),
3.50 (s, 174H), 3.73 (q, 6H), 4.03 (t, 2H), 7.22 (t, 1H).
Synthesis of Zr-UiO: Zr-UiO was synthesized using a reported procedure.25 1,4-benzene
dicarboxylic acid (37.7 mg, 0.23 mmol) and ZrCl4 (52.9 mg, 0.23 mmol) were dissolved in
26.4 mL DMF. This solution was sealed in a Teflon-lined autoclave and heated in an oven at
120 °C for 24 h. After cooling to room temperature, the resulting solid was isolated be
centrifugation at 10,000 rpm for 10 min. After removing the supernatant, the solid was
washed three times, once using 20 mL of DMF, then twice using 10 mL of ethanol each
time. For each wash, the particles were redispersed by sonication and then recovered by
centrifugation at 10,000 rpm for 10 min. Yield: 48.8 mg (76.9%)
Synthesis of Hf-UiO: 1,4-Benzene dicarboxylic acid (45.1 mg, 0.27 mmol) and HfCl4 (87.1
mg, 0.27 mmol) were dissolved in 26.4 mL of DMF, and acetic acid (13.2 μL, 0.23 mmol)
was added. This solution was sealed in a Teflon-lined autoclave and heated in an oven at
100 °C for 48 h. After cooling to room temperature, the resulting solid was isolated and
washed as described for Zr-UiO. Yield: 77.6 mg (78.2%)
Synthesis of Hf-UiO@SiO2: Hf-UiO (60.0 mg) was dispersed in 10 mL of ethanol. This
dispersion was added to a solution of 2.0 mL ammonium hydroxide (14.8 M, 30.0 mmol) in
138 mL of ethanol, then TEOS (18.0 μL, 81.2 μmol) was added. The final 150-mL reaction
mixture contained 0.4 mg of particles/mL with 0.2 M NH4OH and 0.406 mM TEOS. The
reaction was stirred at room temperature for 2 h, then the resulting particles were isolated by
centrifugation and washed with ethanol, as described for Zr-UiO. Yield: 52.8 mg (76.4%)
Synthesis of Hf-UiO@SiO2@PEG: Hf-UiO@SiO2 (45.0 mg) was dispersed in a 10-mL
solution of (OEt)3Si-PEG2000-OCH3 (15.0 mg, 6.8 μmol) in ethanol. This dispersion was
added to a solution of 0.305 mL ammonium hydroxide (14.8 M, 4.5 mmol) in 4.7 mL of
ethanol. The final 15-mL reaction mixture contained 3 mg of particles/mL with 0.3 M
NH4OH and 0.45 mM PEG. The reaction was stirred at room temperature for 21 h, then the
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resulting particles were isolated by centrifugation and washed with H2O and methanol, as
described for Zr-UiO. Yield: 40.5 mg (71.8%)
Synthesis of Hf-NMOF: 1,4-Benzene dicarboxylic acid (21.9 mg, 0.13 mmol) and HfCl4
(42.3 mg, 0.13 mmol) were dissolved in 26.4 mL of DMF. This solution was sealed in a
Teflon-lined autoclave and heated in an oven at 100 °C for 48 h. After cooling to room
temperature, the resulting solid was isolated and washed as described for Zr-UiO. Yield:
41.6 mg (86.4%)
Synthesis of Hf-NMOF@SiO2: Hf-NMOF (60.0 mg) was dispersed in 10 mL of ethanol.
This dispersion was added to a solution of 1.52 mL ammonium hydroxide (14.8 M, 22.5
mmol) in 138.47 mL of ethanol, then TEOS (9.0 μL, 40.6 μmol) was added. The final 150-
mL reaction mixture contained 0.4 mg of particles/mL with 0.15 M NH4OH and 0.20 mM
TEOS. The reaction was stirred at room temperature for 1 h, then the resulting particles were
isolated by centrifugation and washed with ethanol, as described for Zr-UiO. Yield: 56.4
mg (94.0%)
Synthesis of Hf-NMOF@SiO2@PEG: The same procedure as for Hf-UiO@SiO2@PEG
was used, except Hf-NMOF@SiO2 was used instead of Hf-UiO@SiO2. Yield: 45.0 mg
(100%).
Results and discussion
Synthesis and characterization of Zr- and Hf-UiO
Nanoparticles of the UiO-66 MOF with the formula Zr6O6(OH)4(BDC) (Zr-UiO, BDC =
1,4-benzenedicarboxylate) were synthesized by the reported solvothermal method.25 Equal
molar amounts of ZrCl4 and benzene dicarboxylic acid (H2BDC) were dissolved in N,N′-
dimethylformamide (DMF) and heated at 120 °C in a sealed vessel for 24 h. The resulting
particles were observed by scanning electron microscopy (SEM) and transmission electron
microscopy (TEM) to be ~50 nm cubes, many intergrown to form clusters up to ~200 nm in
size (Fig. 1A, S1A). The reported crystal structure of UiO-66 was solved using powder X-
ray diffraction (PXRD) data.25 Zr-UiO was shown to match the UiO-66 structure by PXRD
(Fig. 1C). The peak at 12°, which does not appear in the simulated pattern, is due to solvent
molecules within the pores of the as-synthesized MOF, as it disappears when the MOF is
desolvated.25
The Hf analog of Zr-UiO was also synthesized by a solvothermal method, but using the
same conditions as for Zr-UiO resulted in poorly crystalline particles intergrown into
clusters as large as 3 μm, with a large size distribution. In order to obtain more
monodisperse smaller particle clusters with better crystallinity, small amounts of acetic acid
were added as a modulator. Hf-UiO (Hf6O6(OH)4(BDC)) was synthesized by heating a
solution of equal molar HfCl4 and H2BDC with 0.85 equivalents of acetic acid in DMF at
100 °C in a sealed vessel for 48 h. Addition of terminating ligands has recently been
introduced as a method to control NMOF growth.27–29 Acetic acid competes with BDC for
coordination with the metal cations of Hf-UiO and presumably also modulates growth by
binding with soluble Hf4+ species in solution. The resulting particles were observed by SEM
and TEM to be 50–200 nm clusters of intergrown ~30 nm cubes (Fig. 1B, S1B). The PXRD
pattern of Hf-UiO is very similar to that of Zr-UiO, indicating their isostructural nature
(Fig. 1C). Thermogravimetric analysis (TGA) of Zr-UiO and Hf-UiO shows 50.2% and
32.4% weight loss, respectively, due to dehydroxylation from 250–300 °C and
decomposition of BDC from 420–520 °C to leave behind ZrO2 and HfO2 (Fig. 1D). The
expected weight losses calculated from the formulas are 55.6% and 43.3% for Zr-UiO and
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Hf-UiO, respectively. The lower weight losses observed could be due to some amorphous
Zr/Hf oxides formed during synthesis and trapped in the pores of the NMOF.
Phantom CT studies
Phantom studies were conducted with Hf-UiO and Zr-UiO to evaluate their X-ray
attenuation properties. Aqueous dispersions of each type of NMOF underwent CT scans
with concentrations ranging from 0.0–.20 M Hf or Zr. For comparison, various
concentrations of Iodixanol, a clinically used iodinated contrast agent, were also scanned.
Hf-UiO contains 57.3 wt% Hf and Zr-UiO contains 37.0 wt% Zr, while Iodixanol contains
49 wt% I. The Hounsfield unit (HU)30 value is an indicator of the ability of a material to
attenuate X-rays with respect to water (0 HU). For images taken at 50 kVp (peak voltage),
the slopes of the lines produced by plotting HU values against Hf/Zr/I concentrations for Hf-
UiO, Zr-UiO, and Iodixanol are 10740±390, 5600±180, and 5390±230 HU/M, respectively
(Fig. 2). These values are consistent with the relative attenuation coefficients of Hf, Zr, and I
at the relevant photon energies, shown in Fig. 2E on a per mol basis, derived from data
reported by NIST (see Supporting Information, Fig. S2).31 The X-ray source produces
photons with a wide energy distribution, with the kVp beingthe maximum, and the lowest
energy photons are removed by filtration.32 In this case, with a kVp of 50 keV, the photon
energy distribution is centered around 22 keV.
Attenuation coefficients increase sharply at the K shell electron binding energy (K edge) of
a particular element. K edge energy is higher for heavier elements, and the K edge energies
for Zr, I, and Hf, are 18.0, 33.2, and 65.4 keV, respectively. While Zr has higher attenuation
than I in the 18.0–33.2 eV range, the higher attenuation of I below and above this range
makes the overall attenuation of Zr and I very similar on a per mol basis. Hf has higher
attenuation than both Zr and I by about a factor of two. The enhancement in attenuation
compared to these lighter elements would be even more pronounced at the higher kVp
values (typically 120 kVp) used clinically for imaging human patients, due to the higher
energy of the K edge. A Hf-based CT contrast agent could provide superior contrast at a
lower dose compared to an I-based agent, and could decrease the amount of radiation to
which the patient must be exposed.
Functionalization of Hf-UiO nanoparticles
Based on the encouraging results from phantom studies, we decided to evaluate the potential
of Hf-UiO as a CT contrast agent in vivo. Our previous studies showed that most NMOFs
are not stable under physiological conditions due to the presence of many competing binding
ligands such as phosphate and carbonate ions.33, 34 Indeed it was found that phosphate in
phosphate buffered saline (PBS) can compete with carboxylate groups in Hf-UiO to form
Hf(PO4)x. We have also shown that some of the NMOFs could be coated with an amorphous
shell of silica to slow down the NMOF decomposition so that the imaging or therapeutic
cargoes will not be prematurely lost.21, 24, 34 The silica coating can also facilitate attachment
of siloxy-derived molecules to increase the biocompatibility of the NMOF particles.24, 34
Tetraethyl orthosilicate (TEOS) was added to a dispersion of Hf-UiO in ethanol with
ammonium hydroxide to catalyze hydrolysis and condensation of TEOS to coat the particles
with a layer of amorphous silica (Hf-UiO@SiO2). Hf-UiO@SiO2 looks similar to the bare
particles by TEM (Fig. 3A), but the presence of silica is indicated by the appearance of a Si-
O band in the IR spectrum at 1051 cm−1 (Fig. S4). TGA shows an increase in weight
remaining corresponding to 13.2 wt% SiO2 (Fig. 3C). The zeta potential becomes more
negative, from −24.6 mV for the bare particles to −32.8 mV for the silica-coated particles,
due to deprotonated surface silanol groups.
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When nanoparticles are used in vivo, they must be modified with passivating moieties to
enhance biocompatibility and to prevent aggregation.35–38 Poly(ethylene glycol) (PEG) is a
hydrophilic polymer commonly used to coat nanoparticles due its ability to prevent protein
adsorption and aggregation.36, 37, 39, 40 Many as-synthesized nanoparticles tend to aggregate
when proteins adsorb to the surface or in media with high ionic strength, like blood
plasma.38 The silica shell provides a robust surface for PEG grafting, and PEG would likely
be lost without it. A carboxy-terminated version of PEG was grafted onto bare Hf-UiO, but
was lost, as the MOF surface is prone to corrosion/dissolution under physiological
conditions. A siloxy-terminated version of PEG ((OEt)3Si-PEG2000-OCH3) was synthesized
and grafted onto Hf-UiO@SiO2 by stirring the particles in a solution of (OEt)3Si-PEG2000-
OCH3 in ethanol under basic conditions (NH4OH) to produce Hf-UiO@SiO2@PEG. The
PEGylated particles look similar to the silica-coated particles by TEM (Fig. 3B). TGA
shows an additional weight loss step corresponding to 8.0 wt% PEG. PEG grafting raises the
zeta potential closer to neutral, from −32.8 to −17.3 mV, due to the presence of a neutral
polymer coating. The average size was measured by dynamic light scattering (DLS) to be
246 nm, somewhat larger than then 175 nm and 169 nm average sizes for Hf-UiO@SiO2
and Hf-UiO, respectively. The increase in particle size upon pegylation could partially be
due to slight aggregation of the Hf-UiO@SiO2@PEG particles in 10 mM PBS.
In vivo CT studies
In vivo CT imaging was performed on mice using a micro-CT scanner with a carbon
nanotube X-ray source, which could be synchronized and gated with physiological
signals.41, 42 Mouse respiration and electrocardiography (ECG) traces were monitored to
allow respiration-gated and cardiac-gated scans that minimize image blurriness caused by
the animal’s motion. A 20 g anesthetized mouse was administered 6.5 mg Hf-
UiO@SiO2@PEG (46.4 wt% Hf, 3.0 mg Hf) via tail vein injection. In general, a change in
HU of 10–15 units is considered detectable, while a change of 100 HU or more is more
desirable for unambiguous diagnosis of diseased states.4 The attenuation of the spleen and
liver increased by 131 and 86 HU, respectively, while there was no attenuation enhancement
in the bloodstream, as measured in the heart 15 min after injection (Fig. 4). Based on the
attenuation data from the phantom studies and the sizes of the organs, about 6% of the
particles accumulated in the spleen, while about 50% accumulated in the liver. This result
indicates that the particles were taken up by the mononuclear phagocyte system (MPS), as
the spleen and liver are rich in macrophages. This may be due to the relatively large size of
UiO@SiO2@PEG particles, as particles (and aggregates) larger than about 200 nm tend to
be quickly filtered by the tissue in the spleen,38 and those larger than about 500 nm tend to
be taken up readily by macrophages.43
Small Hf-NMOF for in vivo CT
Smaller Hf-NMOF particles (Hf-NMOF) were made in hopes that smaller particles would
circulate longer and allow blood pool imaging. Hf-NMOF was synthesized by heating a
solution of equal molar HfCl4 and H2BDC in DMF at 100 °C in a sealed vessel for 48 h.
This is the same method as used for Hf-UiO, but the concentration of starting materials was
lowered and the acid modulator was eliminated in order to decrease the size of the particles.
The resulting spherical particles were about 50 nm in diameter by SEM (Fig. 5A). TGA
showed that Hf-NMOF has the same Hf content as Hf-UiO (57.3 wt%), but PXRD showed
that the smaller particles are amorphous. Hf-NMOF was coated with silica and then
PEGylated, in a manner similar to Hf-UiO, to result in Hf-NMOF@SiO2@PEG particles
that contain 9.1 wt% SiO2, 10.8 wt% PEG, and 46.5 wt% Hf, as determined by TGA. DLS
in 10 mM PBS showed an average size of 102 nm, compared to 246 nm for the
corresponding larger Hf-UiO@SiO2@PEG particles (Fig. S5). A test for non-specific
protein adsorption was done to determine how Hf- NMOF@SiO2@PEG may behave in the
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bloodstream. Bovine serum albumin (BSA) was added to Hf- NMOF@SiO2@PEG in a 5:1
ratio (by weight) and particle size was monitored by DLS over 95 min. Aggregation due to
protein adsorption would be apparent by an increasing Z-average (an intensity-weighted
measurement of particle diameter) and a decreasing signal intensity due to sedimentation of
large aggregates. The Z-average stayed within a small range (192–200 nm) over the course
of the experiment, and the signal intensity (counts) remained fairly constant, indicating the
stability of Hf-NMOF@SiO2@PEG against aggregation in the presence of BSA (Fig. 5B).
In vivo CT imaging was done using Hf-NMOF@SiO2@PEG. A 20 g anesthetized mouse
was administered 4.3 mg Hf-NMOF@SiO2@PEG (46.5 wt% Hf, 2.0 mg Hf) via tail vein
injection. As with the larger particles, these smaller particles accumulated in the spleen and
liver (Fig. S6), with attenuation increases of 101 and 41 HU, respectively, and no increase in
attenuation in the bloodstream. The CT results obtained using Hf-NMOF@SiO2@PEG are
similar to those with larger Hf-UiO@SiO2@PEG. It is possible that these smaller particles
still form aggregates in the bloodstream that are big enough to be filtered by spleen or easily
recognized by the MPS due to ineffective PEG shielding.
Conclusions
Nanoscale metal-organic frameworks with Zr or Hf metal connecting points have been
synthesized and evaluated for their potential as CT contrast agents. Both amorphous Hf-
NMOF and crystalline Hf-NMOF of the UiO structure were prepared for the first time, and
coated with silica and then functionalized with PEG to make the particles suitable for in vivo
CT imaging. PEGylated Hf-NMOFs could be used as contrast agents for imaging the spleen
or liver. The NMOF platform provides a promising strategy for incorporating high loadings
of heavy elements into nanoparticles that can be surface-functionalized for enhanced
biocompatibility and in vivo performance.
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TEM images of (A) Zr-UiO and (B) Hf-UiO. (C) Experimental PXRD patterns of Zr-UiO
and Hf-UiO, along with the simulated pattern for Zr-UiO. (D) TGA curves of Zr-UiO and
Hf-UiO.
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CT phantom images of (A) Hf-UiO, (B) Zr-UiO, and (C) Iodixanol dispersed in water.
From the top, counterclockwise, the slots have [Hf/Zr/I] = 0, 0.05, 0.10, 0.15, and 0.20 M.
(D) X-ray attenuation as a function of [Hf/Zr/I] for Hf-UiO, Zr-UiO, and Iodixanol at 50
kVp. (E) Attenuation coefficient vs. photon energy for Hf, Zr, and I.
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TEM images of (A) Hf-UiO@SiO2 and (B) Hf-UiO@SiO2@PEG. (C) TGA of Hf-UiO,
Hf-UiO@SiO2, and Hf-UiO@SiO2@PEG. (D) Size distribution by number obtained by
DLS of Hf-UiO, Hf-UiO@SiO2, and Hf-UiO@SiO2@PEG in 10 mM PBS.
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(A,B) Sagittal and (C,D) axial CT slices of a mouse pre-contrast and 15 min after injection
of Hf-UiO@SiO2@PEG. The areas of increased attenuation are outlined, and the labels are:
1-spleen (+131 HU), 2-liver (+86 HU), 3-heart, 4-lungs.
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(A) SEM image of Hf-NMOF@SiO2@PEG. (B) DLS stability test of Hf-
NMOF@SiO2@PEG in 10 mM PBS in the presence of bovine serum albumin.
deKrafft et al. Page 14











































































































































































































J Mater Chem. Author manuscript; available in PMC 2013 January 01.
